Dtsch Med Wochenschr 2012; 137(05): 194-197
DOI: 10.1055/s-0031-1292889
Kardiologie | Commentary
Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Persistierendes Foramen ovale/Vorhofseptumdefekt: Diagnostik und Therapie

Patent foramen ovale/atrial septal defect: diagnosis and treatment
T. Zeus
1   Klinik für Kardiologie, Pneumologie, Angiologie, Herzzentrum der Heinrich- Heine-Universität Düsseldorf
,
G. Nickenig
2   Medizinische Klinik II – Innere Medizin (Kardiologie, Angiologie und Pneumologie), Universitätsklinikum Bonn
› Author Affiliations
Further Information

Publication History

Publication Date:
25 January 2012 (online)

 
  • Literatur

  • 1 Balzer J, van Hall S, Rassaf T et al. Feasibility, safety, and efficacy of real-time three-dimensional transoesophageal echocardiography for guiding device closure of interatrial communications: initial clinical experience and impact on radiation exposure. Eur J Echocardiogr 2010; 11: 1-8
  • 2 Baumgartner H, Bonhoeffer P, De Groot NM et al. Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31: 2915-2957
  • 3 Butera G, Carminati M, Chessa M et al. Percutaneous versus surgical closure of secundum atrial septal defect: comparison of early results and complications. Am Heart J 2006; 151: 228-234
  • 4 Calvert PA, Rana BS, Kydd AC et al. Patent foramen ovale: anatomy, outcomes, and closure. Nat Rev Cardiol 2011; 8: 148-160
  • 5 Delgado V, van der Kley F, Schalij MJ et al. Optimal imaging for planning and guiding interventions in structural heart disease: a multi-modality imaging approach. Eur Heart J 2010; 12: E10-E23
  • 6 Furlan AJ for the CLOSURE I Investigators. A prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with a stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Presented at the American Heart Association Meeting, 15th November 2010
  • 7 Krumsdorf U, Ostermayer S, Billinger K et al. Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004; 43: 302-309
  • 8 Lindinger A, Schwedler G, Hense HW. Prevalence of congenital heart defects in newborns in Germany: Results of the first registration year of the PAN Study (July 2006 to June 2007). Klin Padiatr 2010; 222: 321-326
  • 9 O'Gara PT, Steven R, Messe SR et al. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: A call for completion of randomized clinical trials. Circulation 2009; 119; 2743-2747
  • 10 Rigatelli G, Dell'Avvocata F, Cardaioli P et al. Permanent right-to-left shunt is the key factor in managing patent foramen ovale. J Am Coll Cardiol 2011; 58: 2257-2261
  • 11 Schwamm H, Wassertheil-Smoller S, Turan TN et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Assoiciation/American Stroke Association. Stroke 2011; 42: 227-276
  • 12 Taniguchi M, Akagi T, Watanabe N et al. Application of real-time threedimensional transesophageal echocardiography using a matrix array probe for transcatheter closure of atrial septal defect. J Am Soc Echocardiogr 2009; 22: 1114-1120
  • 13 Torbey E, Thompson PD. Patent foramen ovale: thromboembolic structure or incidental finding?. Conn Med 2011; 75: 97-105